Recombinant Bispecific Antibodies to the Human ErbB2 Receptor and Interferon-Beta

The development of and research into new therapies that can selectively and effectively destroy tumor cells that overexpress the ErbB2 receptor is a pressing task. Recently, research into the use of type I interferons in the treatment of cancer has intensified. Cytokine therapy is aimed at activatin...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Acta Naturae
Glavni autori: Panina, A. A., Rybchenko, V. S., Solopova, O. N., Balabashin, D. S., Yakimov, S. A., Aliev, T. K., Dolgikh, D. A., Sveshnikov, P. G., Kirpichnikov, M. P.
Format: Artigo
Jezik:Inglês
Izdano: A.I. Gordeyev 2020
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7385087/
https://ncbi.nlm.nih.gov/pubmed/32742732
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.32607/actanaturae.10903
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items